Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We explore the effect of randomized treatment, comparing intensive to standard glucose-lowering strategies on major cardiovascular outcomes, death, and severe adverse events in older versus younger participants in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. RESEARCH DESIGN AND METHODS: Participants with type 2 diabetes (n = 10,251) with a mean age of 62 years, a median duration of diabetes of 10 years, and a median A1C of 8.1% (65 mmol/mol) were randomized to treatment strategies targeting either A1C <6.0% (42 mmol/mol) or 7.0–7.9% (53–63 mmol/mol) and followed for a mean of 3.7 years. Outcomes were analyzed within subgroups defined by baseline age (<65 vs. ≥65 years). RESULTS: Older and younger ACCORD participants achieved similar intensive-arm A1C levels and between-arm A1C differences. Within the older subgroup, similar hazards of the cardiovascular primary outcome and total mortality were observed in the two arms. While there was no intervention effect on cardiovascular mortality in the older subgroup, there was an increased risk in the intensive arm for the younger subgroup (older hazard ratio [HR] = 0.97; younger HR = 1.71; P = 0.03). Regardless of intervention arm, the older subgroup experienced higher annualized rates of severe hypoglycemia (4.45% intensive and 1.36% standard) than the younger subgroup (2.45% intensive and 0.80% standard). CONCLUSIONS: Intensive glucose lowering increased the risk of cardiovascular disease and total mortality in younger participants, whereas it had a neutral effect in older participants. The intensive to standard relative risk of severe hypoglycemia was similar in both age subgroups, with higher absolute rates in older participants within both treatment arms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“More recent glucoselowering trials such as the Action to Control Cardiovascular Risk in Diabetes (ACCORD) (10), Action in Diabetes and Vascular Disease (ADVANCE) (11), and the Veterans Affairs Diabetes Trial (12) included older adults; however, they have not reported the effects of the glycemic interventions according…”
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515 · cited 1×
“anticipated to be among persons aged 75 and older (2).”
BackgroundKirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274 · cited 2×
“The recent 2012 American Diabetes Association Consensus Report emphasizes a need to stratify targets based on comorbid illness and functional status, among other factors, rather than on age alone (17).”
BackgroundBonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Self-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Furlong, W. J., Feeny, D. H., Torrance, G. W., & Barr, R. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002092 · Cited by 751
Cited by
Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.005 · Cited by 1,787
“However, in established T2D, it is a relatively weak modifiable risk factor compared with hypertension, dyslipidemia, and (unfortunately in many populations) cigarette smoking.(15,16)”
BackgroundType 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Japanese Clinical Practice Guideline for Diabetes 2016
Haneda, M., Noda, M., Origasa, H., Noto, H., Yabe, D., Fujita, Y., Goto, A., Kondo, T., & Araki, E. (2018) · Diabetology International · doi:10.1007/s13340-018-0345-3 · Cited by 319
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska, K. J., Krumholz, H., Soones, T., & Lee, S. J. (2016) · JAMA · doi:10.1001/jama.2016.0299 · Cited by 309
Intermittent Fasting in Cardiovascular Disorders—An Overview
Malinowski, B., Zalewska, K., Węsierska, A., Sokołowska, M. M., Socha, M., Liczner, G., Pawlak-Osińska, K., & Wiciński, M. (2019) · Nutrients · doi:10.3390/nu11030673 · Cited by 290
“The ACCORD trial confirmed greater risk of cardiovascular events during the presence of hypoglycemia in both older and younger individuals [98].”
BackgroundOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Intermittent Fasting and Metabolic Health
Vasim, I., Majeed, C. N., & DeBoer, M. D. (2022) · Nutrients · doi:10.3390/nu14030631 · Cited by 285
Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes
The ACCORD Study Group (2016) · Diabetes Care · doi:10.2337/dc15-2283 · Cited by 193
“Indeed, two ACCORD analyses found that the excess mortality in the intensive group was most apparent in participants whose HbA1c levels remained high despite allocation to the intensive group and use of therapeutic strategies seeking nearly normal glucose levels (18,19).”
BackgroundMcKenzie, A. L., Hallberg, S. J., Creighton, B. C., Volk, B. M., Link, T. M., Abner, M. K., Glon, R. M., McCarter, J. P., Volek, J. S., & Phinney, S. D. (2017) · JMIR Diabetes · doi:10.2196/diabetes.6981 · Cited by 176
Benefits and harms of intensive glycemic control in patients with type 2 diabetes
Rodriguez-Gutierrez, R., Gonzalez-Gonzalez, J. G., Zuñiga-Hernandez, J. A., & McCoy, R. G. (2019) · BMJ · doi:10.1136/bmj.l5887 · Cited by 152
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial
Leiter, L. A., Teoh, H., Braunwald, E., Mosenzon, O., Cahn, A., Kumar, K. M. P., Smahelova, A., Hirshberg, B., Stahre, C., Frederich, R., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2868 · Cited by 87
Self-citationKawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Metadata
- Authors
- Miller, M. E., Williamson, J. D., Gerstein, H. C., Byington, R. P., Cushman, W. C., Ginsberg, H. N., Ambrosius, W. T., Lovato, L., Applegate, W. B., & for the ACCORD Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-02-11
- Volume
- 37
- Issue
- 3
- Pages
- 634-643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2134625795
- Cited by
- 129
- References
- 19
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.